Ashland Inc. Q3 FY2025 earnings call

Management Statement and Operational Highlights

• Portfolio Optimization: Complete, with all 4 business units achieving strong EBITDA margins.
• Restructuring: Ahead of schedule, with run rate savings nearing completion and carryover benefits in fiscal '26.
• Manufacturing Optimization: $60 million program with HEC network consolidation complete, and additional cost actions ramping into Q4 and fiscal 2026.
• Innovation: Ahead of plan, with $10 million in incremental innovation-driven sales already achieved, meeting full year target.
• Market Resilience: Roughly 85% of portfolio tied to noncyclical consumer end markets, providing resilience in uncertain macroeconomic environments.

Segment Performance

• Life Sciences: Sales were $162 million in Q3, down 17% year-over-year. Adjusted EBITDA was $54 million, down 8% year-over-year, with a margin of 33% for the second consecutive quarter. Organic sales declined just 1% year-over-year, with pharma growth offset by softness in other markets.
• Personal Care: Sales were $147 million in Q3, down 16% year-over-year. Adjusted EBITDA declined 20% to $41 million, with the business delivering an EBITDA margin in line with fiscal 2025 targets. Early signs of recovery are seen across business lines.
• Specialty Additives: Sales declined 13% to $131 million in Q3. Adjusted EBITDA declined 32% year-over-year to $26 million. The HEC network consolidation was a key driver to improve cost efficiency and margins.
• Intermediates: Sales were $33 million, down from the same period last year. Adjusted EBITDA was $7 million, with a margin of 21.2%. The business secured advanced manufacturing tax credits to partially offset pressures.

Guidance

• Full year fiscal 2025 sales expected to be approximately $1.825 billion to $1.85 billion.
• Adjusted EBITDA expected in the range of $400 million to $410 million.
• Q4 expected to have strong cash generation, with $7.5 million in cost savings expected in Q4 from restructuring.
• Manufacturing network optimization initiatives making solid progress, supporting continued margin strength.

Risks

• Tariffs: Regulatory uncertainties remain, though no material direct impact on fiscal 2025 results expected.
• Specialty Additives: Impacted by weak coating season, ongoing pressures in China, and overcapacity in certain regions.
• Intermediates: Navigating a difficult supply-demand landscape, particularly in Europe, with pricing and production volumes under pressure.

Question and Answer

Q: Christopher Parkinson of Wolfe Research asked about visibility into fiscal year '26 and incremental margins returning to historical ranges.

A: Guillermo Novo and William C. Whitaker discussed demand stabilization, cleaner portfolio, and ongoing self-help actions, noting Personal Care and pharma demand should remain stable, and Specialty Additives may see upside if interest rates move. William also mentioned $12 million carryover restructuring savings and $60 million manufacturing optimization flow-through details.

Q: David Begleiter of Deutsche Bank inquired about cost side incremental savings in '26 vs '25.

A: Guillermo and William explained $30 million restructuring savings with $12 million carryover next year, and $60 million manufacturing optimization with flow-through dependent on inventory and S&OP for next year, expecting a meaningful step-up in '26.

Q: Josh Spector of UBS asked about conviction in Q4 sales step-up and segment contributions.

A: Guillermo and William noted Personal Care lapping company-specific items, pharma cellulosics innovation, and Specialty Additives wins in industrial and performance specialties, expecting low single-digit volume changes and stable pricing.

Q: John McNulty of BMO questioned innovation target changes and '26-27 growth.

A: Guillermo discussed core innovation and new platform innovations, highlighting process and product innovations with momentum in globalized initiatives, and expected ramping of innovations in '26 and beyond.

Q: John Roberts of Mizuho asked about goodwill impairment and Section 232 tariffs impact.

A: William explained goodwill impairment tied to market cap relative to carrying value, and Alessandra noted pharma customers are on a wait-and-see mode regarding Section 232 tariffs with no immediate meaningful changes expected.

Q: Laurence Alexander of Jefferies inquired about innovation commercialization lag and SG&A impact.

A: William discussed varying lags by technology, with TVO and novel cellulosics having different investment phases, but emphasizing readiness to add R&D and technical resources as customers commit to projects.